studies

mRCC - L1 - PDL1 positive, anti-PD-(L)1 vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsJAVELIN Renal 101( PDL1>1%), 2019 0.69 [0.58; 0.83] 0.69[0.58; 0.83]JAVELIN Renal 101( PDL1>1%), 201910%560NAnot evaluable PFS (extension)detailed resultsJAVELIN Renal 101( PDL1>1%), 2019 0.62 [0.49; 0.78] 0.62[0.49; 0.78]JAVELIN Renal 101( PDL1>1%), 201910%560NAnot evaluable progression or deaths (PFS)detailed resultsIMmotion-150 (At - PDL1>1%), 2018 1.03 [0.63; 1.68] IMmotion-150 (AtB - PDL1>1%), 2018 0.64 [0.38; 1.08] JAVELIN Renal 101( PDL1>1%), 2019 0.61 [0.47; 0.79] 0.71[0.52; 0.97]IMmotion-150 (At - PDL1>1%), 2018, IMmotion-150 (AtB - PDL1>1%), 2018, JAVELIN Renal 101( PDL1>1%), 2019343%784moderatenot evaluable objective responses (ORR)detailed resultsIMmotion-150 (At - PDL1>1%), 2018 1.06 [0.46; 2.42] IMmotion-150 (AtB - PDL1>1%), 2018 2.34 [1.05; 5.20] JAVELIN Renal 101( PDL1>1%), 2019 3.39 [2.38; 4.82] 2.19[1.11; 4.33]IMmotion-150 (At - PDL1>1%), 2018, IMmotion-150 (AtB - PDL1>1%), 2018, JAVELIN Renal 101( PDL1>1%), 2019370%784moderatenot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-06-02 02:00 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 152 - treatments: 367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,854,374,1073,953,672,1080,862,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons